Evidence map›Paper›PMID 34197702›Full record

ArticleCancer communications (London, England)2021

The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021.

Feng-Hua Wang, Xiao-Tian Zhang, Yuan-Fang Li, Lei Tang, Xiu-Juan Qu, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Hong Qiu and 24 more

2 registry-linked trialsAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer communications (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 430 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
430citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06078930 recruitingnot on this map

A Multi-center Observational Clinical Study on the Development of Artificial Intelligence-Based Gastric Cancer Screening and Diagnosis Technology Using Multi-Omics Analysis of Tongue Imaging and Tongue Coating

Typeobservational_patient_registrySponsorZhejiang Cancer HospitalRan2021 to 2026Enrolled100,000ConditionsGastric Cancer, Tongue Images, DiagnosisArmsTongue imaging, tougue coating, saliva, gastric juice, and feces
NCT06848400 narecruitingnot on this mapstarted 2025, after this paper: background citation

A Multicenter, Prospective Study of Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios

TypeinterventionalSponsorNanfang Hospital, Southern Medical UniversityRan2025 to 2026Enrolled482ConditionsGastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric DysplasiaArmsAI-integrated Capsule Gastroscopy (ACG) examination, Electronic gastroduodenoscopy (EGD) examination
3 · Its place in the literature

Who cites it

430 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Article

370 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Feng-Hua WangDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Xiao-Tian ZhangDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Yuan-Fang LiDepartment of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Lei TangDepartment of Radiology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Xiu-Juan QuDepartment of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China.
Jie-Er YingDepartment of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, 310006, P. R. China.
Jun ZhangDepartment of Medical Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, P. R. China.
Ling-Yu SunDepartment of Surgical Oncology, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, 150001, P. R. China.
Rong-Bo LinDepartment of Medical Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, 350000, P. R. China.
Hong QiuDepartment of Medical Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
Chang WangCancer Center of The First Hospital of Jilin University, Changchun, Jilin, 130021, P. R. China.
Miao-Zhen QiuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Mu-Yan CaiDepartment of Pathology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Qi WuDepartment of Endoscopy Center, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Hao LiuDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Wen-Long GuanDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Ai-Ping ZhouDepartment of Oncology, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, P. R. China.
Yu-Jing ZhangDepartment of Radiotherapy, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Tian-Shu LiuDepartment of Medical Oncology, Zhongshan Hospital Affiliated to Fudan University, Shanghai, 200032, P. R. China.
Feng BiDepartment of Abdominal Oncology, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, P. R. China.
Xiang-Lin YuanDepartment of Medical Oncology, Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, 430030, P. R. China.
Sheng-Xiang RaoDepartment of Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, P. R. China.
Yan XinPathology Laboratory of Gastrointestinal Tumor, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China.
Wei-Qi ShengDepartment of Pathology, Zhongshan Hospital Affiliated to Shanghai Fudan University, Shanghai, 200032, P. R. China.
Hui-Mian XuDepartment of Gastrointestinal Oncology Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, 110001, P. R. China.
Guo-Xin LiDepartment of General Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, 510515, P. R. China.
Jia-Fu JiDepartment of Gastrointestinal Surgery, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Zhi-Wei ZhouDepartment of Gastric Surgery, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.
Han LiangDepartment of Gastric Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin, 300060, P. R. China.
Yan-Qiao ZhangDepartment of Gastrointestinal Medical Oncology, Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, 150081, P. R. China.
Jing JinDepartment of Radiation Oncology, Shenzhen Center, Cancer Hospital of Chinese Academy of Medical Sciences, Shenzhen, 518000, P. R. China.
Lin ShenDepartment of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, P. R. China.
Jin LiDepartment of Oncology, East Hospital Affiliated to Shanghai Tongji University, Shanghai, 200120, P. R. China.
Rui-Hua XuDepartment of Medical Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, 510060, P. R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There exist differences in the epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selections between gastric cancer patients from the Eastern and Western countries. The Chinese Society of Clinical Oncology (CSCO) has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually. Taking into account regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China. The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis, treatment, follow-up, and screening of gastric cancer. Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines, this updated guideline integrates the results of major clinical studies from China and overseas for the past year, focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations. For the comprehensive treatment of non-metastatic gastric cancer, attentions were paid to neoadjuvant treatment. The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated. For the comprehensive treatment of metastatic gastric cancer, recommendations for immunotherapy were included, and immune checkpoint inhibitors from third-line to the first-line of treatment for different patient groups with detailed notes are provided.

Indexed as

Stomach NeoplasmsChinaHumansMedical OncologySocieties, MedicaladjuvantchemotherapyChinese Society of Clinical Oncology (CSCO)diagnosisgastric cancerimmunotherapyneoadjuvantradiotherapysurgerytargeted therapy

Identifiers

PMID34197702
PMCPMC8360643

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.